2020中国系统性红斑狼疮诊疗指南

2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus

系统性红斑狼疮(SLE)是一种系统性自身免疫病,其诊断和治疗均很复杂。在我国制订既符合国际指南制订标准又贴近中国临床实践的SLE诊疗指南势在必行。本指南由中华医学会风湿病学分会、国家皮肤与免疫疾病临床医学研究中心、中国系统性红斑狼疮研究协作组联合牵头发起,采用推荐意见分级的评估、制订及评价(grading of recommendations assessment,development and evaluation,GRADE)分级体系和国际实践指南报告标准(RIGHT),就我国一线风湿免疫科医师关注的12个临床问题,给出了较为详细的循证推荐,旨在提高SLE诊疗的科学性,提高以患者为中心的医疗服务质量。

Systemic lupus erythematosus(SLE),a complex and heterogeneous autoimmune disease,represents a significant challenge for both diagnosis and treatment.In 2019,under the leadership of the Chinese Rheumatology Association,a multidisciplinary guideline development group was established.The objective was to develop an evidence-based diagnosis and treatment guideline for SLE in China based on emerging new evidence.The guideline was registered at International Practice Guidelines Registry Platform(IPGRP-2019CN022).The grading of recommendations assessment,development and evaluation(GRADE)approach was used to rate the quality of evidence and the strength of recommendations,and the RIGHT(Reporting Items for Practice Guidelines in Healthcare)checklist was followed to report the guideline.The guideline provides recommendations for the SLE classification criteria,disease activity monitoring and assessing,medication principles and considerations organ and system involvement and management of patients during pregnancy.This guideline is intended to serve as a tool for Chinese clinicians for the best decisions-making on diagnosis and treatment of SLE.